¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"high dose rate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
¿µ¹® skin dose ÇÑ±Û ÇǺμ±·®
¼³¸í   
  1. ÇǺÎÇ¥¸é¿¡¼­ÀÇ ¹æ»ç¼±ÀÇ °øÁß¼±·®À¸·Î ¿©±â¿¡´Â 1Â÷¹æ»ç¼±°ú ÈĹæ»ê¶õÀÌ Æ÷ÇԵȴÙ. 2. ÇǺο¡ Èí¼öµÇ´Â ¼±·®.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high field magnetic resonance scanner
    °íÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
  • high flow method
    °íÀ¯·®¹ý
  • high forceps
    °íÀ§Áý°Ô, À§ÂÊÁý°Ô
  • high forceps delivery
    °íÀ§Áý°ÔºÐ¸¸(¼ú), °íÀ§°âÀںи¸(¼ú)
  • high frequency current
    °íÁÖÆÄÀü·ù
  • high frequency filter
    °íÁÖÆÄ¿©°ú±â, °íÁ֯İŏ£°³
  • high frequency recombination
    °íºóµµÀçÁ¶ÇÕ
  • high frequency transducing lysate
    °íºóµµÇüÁúµµÀÔ¿ëÇØ¹°
  • high frequency transduction
    °íºóµµÇüÁúµµÀÔ
  • high insertion
    °íÀ§ºÎÂø
  • high intensity proton flow
    °í°­µµ¾çÀÚÈ帧, °í°­µµ¾çÀÚÀ¯µ¿
  • high pelvic position
    ³ôÀº°ñ¹ÝÀÚ¼¼
  • high polymer chemistry
    °íºÐÀÚÈ­ÇÐ
  • high potency
    1. °íÈ¿´É, °í¿ª°¡ 2. °íÀáÀç·Â
  • high power application
    °íÃâ·ÂÀû¿ë
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • radiation absorbed dose
    Èí¼ö¼±·®
  • skin dose
    ÇǺμ±·®
  • therapeutic dose
    Ä¡·á¿ë·®, Ä¡·á¼±·®
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • rate limiting enzyme
    ¼ÓµµÁ¶ÀýÈ¿¼Ò
  • rate
    1. ¼Óµµ, 2. À², 3. Á¤µµ, 4. ¾ç
  • abortion rate
    À¯»êÀ²
  • actual death rate
    ½ÇÁ¦»ç¸Á·ü
  • adjusted death rate
    (¢¡standardized death rate) Ç¥ÁØÈ­»ç¸Á·ü
  • alveolar ventilation rate
    ÇãÆÄ²Ê¸®È¯±âÀ², ÆóÆ÷ȯ±âºñ
  • attack rate
    ¹ßº´·ü
  • basal metabolic rate
    ±âÃÊ´ë»çÀ²
  • birth rate
    Ãâ»ý·ü
  • blood flow rate
    Ç÷·ù·®, Ç÷·ù¼Óµµ
  • cardiac rate
    (¢¡heart rate) ½ÉÀå¹Úµ¿¼ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high-pressure liquid chromatography
    °í¾Ð·Â¾×üũ·Î¸¶Åä±×·¡ÇÇ
  • high-threshold cell
    °í¹®Åΰª¼¼Æ÷
  • high forceps delivery
    °íÀ§Áý°ÔºÐ¸¸¼ú
  • high residue diet
    °íÀÜ·ù½ÄÀÌ
  • high tone deafness
    °íÀ½³­Ã»
  • high altitude pulmonary edema
    °í»êÆóºÎÁ¾
  • high forceps
    °íÀ§Áý°Ô, À§ÂÊÁý°Ô
  • high frequency filter
    °íÁ֯İŏ£°³, °íÁÖÆÄ¿©°ú
  • high intensity proton flow
    °í°­µµ¾çÀÚÈ帧, °í°­µµ¾çÀÚÀ¯µ¿
  • high-output heart failure
    °í¹ÚÃâ½ÉÀå±â´É»ó½Ç, °í¹ÚÃâ½ÉÀåºÎÀü
  • high-pass filter
    °íÁÖÆÄÅë°ú°Å¸£°³, °íÁÖÆÄÅë°úÇÊÅÍ
  • high risk group
    °íÀ§Çèµµ±º
  • high insertion
    °íÀ§ºÎÂø
  • high resolution
    °íÇØ»ó
  • high signal
    °í½ÅÈ£
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • MTD=ÊÝmaximum toderance dose
    ÃÖ´ë³»¿ë·®.
  • STD= standard test dose
    Ç¥ÁؽÃÇè·®.
  • absorbed dose
    Èí¼ö·®.¹æ»ç¼±Èí¼ö¼±·®(ýåâ¥àÊåÖ).
  • absorbed dose
    Èí¼ö¼±·®
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • acceptable daily dose : ADD
    ÀÏÀÏÇã¿ë·®(ìéìíúÉé»Õá).
  • acceptable dose
    ¿ëÀμ±·®, ¼ö¿ë¼±·®, Çã¿ë¼±·®
  • adult dosage =a. dose
    ¼ºÀη®, ¼ºÀο뷮.
  • arbitrary dose
    ÀÓÀǿ뷮(ìòëòéÄåÖ).
  • fractional dose
    ºÐÇÒ·®.
  • genetic tolerance dose
    À¯ÀüÀû ³»·®(¡­Ò±åÖ).
  • given dose
    ¸í¸ñ¼±·®
  • gonadal dose
    »ý½Ä¼±¼±·®
  • half lethal dose
    ¹ÝÄ¡»ç·®(ÚâöÈÞÝåÖ).
  • head drop dose =HD
    µÎºÎ Ãß¶ô·®(¡­õÍÕªåÖ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • optimal dose ; optimum dose
    ¹æ»ç [¾à¸®,ÇØºÎ,¿¹¹æ]ÃÖÀû·®, ÀûÁ¤·®(ËøËøËâ).
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
  • familial high density lipoprotein def
    °¡Á·¼º °íºñÁ߸®Æ÷´Ü¹éÁú°áÇÌ Áõ.
  • high altitude
    °í¼Ò
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(Ë­ËÛËÛËøÌ´Ë´Ì¡?Ì¡) .
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(ÍÔá¶àõîåúìϹñòÊ¥ñø) .
  • high altitude pulmonary edema
    °íÁöÆóºÎÁ¾.
  • high caloric diet
    °íÄ®·Î¸®½ÄÀÌ.
  • high cellular component
    °í¼¼Æ÷ ±¸¼º ¼ººÐ
  • high dizziness
    °í¼ÒÇö±âÁõ(Ë­ËÛ̴˻̡).
  • high echo area
    °í (ÍÔ) ¿¡ÄÚ ¿ª (æ´)
  • high echo area
    °í ¿¡ÄÚ ±¸¿ª
  • high electron density
    °íÀüÀڹеµ(ÍÔï³í­ÚËöô).
  • high energy bond
    °í¿¡³ÊÁö°áÇÕ.
  • high energy bond
    °í¿¡³ÊÁö °áÇÕ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • transfer rate coefficient
    ÀüÀÌ ¼Óµµ °è¼ö(ï®ì¹áÜÓøÌõâ¦)
  • familial high-density lipoprotein deficiency °¡Á·¼º °í¹Ðµµ ÁöÁú´Ü¹éÁú °áÇÌ (Ê«ðéàõÍÔÚËÓøò·òõ
    Ó±ÛÜòõÌÀù¹)
  • high-density lipoprotein
    °í¹Ðµµ ÁöÁú´Ü¹éÁú(ÍÔÚËÓøò·òõÓ±ÛÜòõ)
  • high-energy bond
    °í(ÍÔ)¿¡³ÊÁö °áÇÕ(Ì¿ùê)
  • high-energy compound
    °í(ÍÔ)¿¡³ÊÁö È­ÇÕ¹°(ûùùêÚª)
  • high-energy ion scattering
    °í(ÍÔ)¿¡³ÊÁö À̿»ê¶õ(ߤկ)
  • high-energy phosphate donor
    °í(ÍÔ)¿¡³ÊÁö ÀÎ»ê°ø¿©ÀÚ(×òß«Íêæ¨í­)
  • high-level promoter
    °íÀ§(ÍÔêÈ)ÇÁ·Î¸ðÅÍ
  • high-lipid lipoprotein
    °íÁöÁú ÁöÁú´Ü¹éÁú(ÍÔò·òõò¢òõÓ±ÛÜòõ)
  • high-mannose glycoproteins
    ´Ù(Òý)¸¸³ë½º ´ç´Ü¹éÁú(ÓØÓ±ÛÜòõ)
  • high-mannose oligosaccharides
    ´Ù(Òý)¸¸³ë½º °ú´çÁú(ÍûÓØòõ)
  • high-mobility group
    °íÀ̵¿µµ ±º(ÍÔì¹ÔÑÓøÏØ)
  • high-performance liquid chromatography
    °í¼º´É(ÍÔàõÒö) ¾×ü(äûô÷) Å©·Î¸¶Åä±×·¡ÇÇ
  • high-potential iron protein
    °íÀüÀ§(ÍÔï³êÈ) ö´Ü¹éÁú(ôÑÓ±ÛÜòõ)
  • high-pressure liquid chromatography
    °í¾Ð(ÍÔäâ) ¾×ü(äûô÷)Å©·Î¸¶Åä±×·¡ÇÇ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cumulative dose
    ÁýÀû¼±·®, ´©ÀûÁ¶»ç·®, ´©Àû¿ë·®, Ãàô¿ë·®
  • curative dose
    ġȿ·®
  • depth dose
    ½ÉºÎ¼±·®
  • fatal dose
    Ä¡»ç·®
  • half lethal dose
    ¹ÝÄ¡»ç·®
  • LD = lethal dose
    Ä¡»ç·®
  • lethal dose [=LD]
    Ä¡»ç·®
  • maintenance dose
    À¯Áö¿ë·®
  • maximal acceptable dose
    ÃÖ´ëÇã¿ë¼±·®
  • maximum permissible dose [=MPD]
    ÃÖ´ëÇã¿ë(¼±)·®
  • median lethal dose
    50%Ä¡»ç·®, Æò±ÕÄ¡»ç·®
  • midbreast dose
    À¯¹æÁß¾ÓÁ¶»ç¼±·®
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • permissible internal dose
    ³»ºÎÇã¿ë¼±·®
  • radiation absorbed dose
    ¶óµå, ¹æ»ç¼±Èí¼ö¼±·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HP halogen phosphorus; handicapped person; haptoglobin; hard palate; Harvard pump; health profession(al...
CPR cardiopulmonary reserve; cardiopulmonary resuscitation; centripetal rub; cerebral cortex perfusion r...
CSR central supply room; chart-stimulated recall [test]; Cheyne-Stokes respiration; continued stay revie...
PR by way of the rectum [Lat. per rectum]; far point [of accommodation] [Lat. punctum remotum]; palindr...
CD cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HIDAC High dose Ara-C
HDMtx High dose Methotrexate
HDC High dose chemotherapy
HDCT High dose chemotherapy
HDMP High dose methyl prednisolone
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • high frequency wave
    °íÁÖÆÄ
  • high intensity proton flow
    °í°­µµ ¾çÀÚÀ¯µ¿
  • high lip line
    »ó¼ø¼±
    À­ ÀÔ¼úÀÇ À§ÂÊ °æ°è.
  • high pain threshold
    °í µ¿Åë ¿ªÄ¡
    ÅëÁõÀ» À¯¹ßÇØ ¹ÝÀÀÀ» ÀÏÀ¸Å°°Ô ÇÏ´Â ÃÖ¼ÒÇÑÀÇ ÀÚ±ØÀÇ °­µµ°¡ ³ôÀº °Í.
  • high power application
    °íÃâ·Â Àû¿ë
  • high protein diet
    °í´Ü¹é ½ÄÀÌ
  • high pull headgear
    »ó¹æ °ßÀÎÇü Çìµå ±â¾î
  • high resolution banding technique
    °íÁ¤µµ ¿°»öü ºÐ¿°¹ý
  • high risk group
    °íÀ§Çèµµ±º
  • high signal intensity
    °í½ÅÈ£ °­µµ
  • high speed core cut biopsy
    °í¼Ó Á᫐ »ý°Ë
  • high surface
    °íÇ¥¸é
  • high threshold mechanical nociceptor
    °í¿ªÄ¡ ±â°è Ä§ÇØ¼ö¿ëü, °í¿ªÄ¡ ±â°è À¯Çؼö¿ë±â
  • high vacuum
    °íÁø°ø
  • high velocity signal loss
    °í¼Óµµ ½ÅÈ£ ¼Ò½Ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
minimal infecting dose <microbiology> The smallest quantity of infectious material regularly producing infection; usually expressed as I.D.50, the quantity causing infection in 50% of a suitable series of animals or cells (cell cultures).
(05 Mar 2000)
minimal lethal dose <pharmacology> The minimal dose of a toxic substance or infectious agent that is lethal, as assayed in various experimental animals (e.g., the least amount of diphtheria toxin that, on an average, kills a 250-g guinea pig within 96 hours after subcutaneous inoculation).
When followed by a subscript (generally "MLD50"), denotes the minimal dose that is lethal to a certain percentage (e.g., 50%) of animals so assayed, LD05.
See: lethal dose.
(05 Mar 2000)
minimal reacting dose The minimal dose of a toxic substance causing a reaction, as manifested in the skin of a series of susceptible test animals; the assay is based on the development of a characteristic, minimal but definite, "standard," focal inflammation (congestion and oedema, induration, degenerative changes, and desquamation of epidermal cells).
(05 Mar 2000)
cumulative dose The total dose resulting from repeated exposures to radiation of the same part of the body or of the whole body.
(05 Mar 2000)
curative dose The quantity of any substance required to effect the cure of a disease or that will correct the manifestations of a deficiency of a particular factor in the diet, effective dose used with therapeutically applied compounds.
Synonym: therapeutic dose.
(05 Mar 2000)
preventive dose The smallest amount of any substance that will prevent occurrence of symptoms of a disease or the consequences of a lack of a particular factor in the diet.
(05 Mar 2000)
sensitizing dose In experimental anaphylaxis, the antigenic inoculum that renders an animal susceptible (sensitive) to anaphylactic shock following a subsequent inoculum (shocking dose) of the same antigen (anaphylactogen).
(05 Mar 2000)
shocking dose In experimental anaphylaxis, the inoculum of antigen that causes anaphylactic shock in an animal sensitised by a previous inoculum (sensitizing dose) of the same antigen.
(05 Mar 2000)
skin dose The quantity of radiation delivered to the skin surface.
(05 Mar 2000)
daily dose The total amount of a remedy that is to be taken within 24 hours.
(05 Mar 2000)
depth dose The dose of radiation at a distance beneath the surface, including secondary radiation or scatter, in proportion to the dose at the surface.
(05 Mar 2000)
divided dose A definite fraction of a full dose; given repeatedly at short intervals so that the full dose is taken within a specified period, usually one day.
Synonym: fractional dose.
(05 Mar 2000)
dose 1. <pharmacology> A quantity to be administered at one time, such as a specified amount of medication.
2. <radiobiology> A general term denoting the quantity of radiation or energy absorbed. For special purposes it must be appropriately qualified. If unqualified, it refers to absorbed dose. Unit of absorbed dose is the rad. The SI unit is the gray (1 Gy = 1 J kg-1 = 100 R).
Origin: Gr. Dosis = a giving
(16 Dec 1997)
dose-effect curve This is a graph drawn to show the relationship between the dose of a drug or other chemical and the magnitude of the graded effect that it produces.
(09 Oct 1997)
dose-escalation A preliminary clinical trial in which the amount of the drug is either periodically increased or increased with each new trial arm that is added. Used to determine how a drug is tolerated in people.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • church rate
    (±³±¸ÀÇ)±³È¸ À¯Áö¼¼
  • continuation rate
    ÀÌ¿ù ÀϺ¯
  • coupon rate
    ä±ÇÀÇ Ç¥¸é ÀÌÀÚÀ²
  • cross rate
    Å©·Î½º ·¹ÀÌÆ®;¿µ.¹Ì ȯ½Ã¼¼
  • death rate
    »ç¸Á·ü(mortality)
  • differential rate
    (öµµ µîÀÇ)ƯÁ¤ ¿îÀÓ·ü
  • discount rate
    ¾îÀ½ ÇÒÀÎÀ²;ÀçÇÒÀÎÀ²
  • economic growth rate
    °æÁ¦ ¼ºÀå·ü 9
  • effective exchange rate
    (±ÝÀ¶)½ÇÈ¿ ȯ½Ã¼¼(ȯÀ²)(±¹Á¦ÅëÈ­±â±ÝÀÌ ´çÇØ±¹°ú ´Ù¸¥ ÁÖ¿ä 20°³±¹ ÅëÈ­ÀÇ È¯½Ã¼¼¸¦ º¹ÇÕ½ÃÄÑ »êÃâÇÏ´Â Áö¼ö)
  • exchange rate
    ȯÀ²
  • fatality rate
    »ç¸Á·ü
  • fixed exchange rate(system)
    °íÁ¤È¯½Ã¼¼(Á¦)
  • flat rate
    °íÁ¤(Á¤¾×)¿ä±Ý
  • floating exchange rate system
    º¯µ¿ ȯÀ²Á¦
  • floating rate
    ÀÚÀ¯ º¯µ¿ ½Ã¼¼;¼±Çϼ¼
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á